Drug Combo Ups Ulcer Risk After Cryoablation in Patients With HCC Drug Combo Ups Ulcer Risk After Cryoablation in Patients With HCC
Patients with hepatocellular carcinoma should be switched from a PD-1, TKI combination to monotherapy after cryoablation. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 7, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
New Guidelines Clarify Use of Systemic Therapy in Advanced HCC New Guidelines Clarify Use of Systemic Therapy in Advanced HCC
The American Gastroenterological Association published recommendations to help guide the management of hepatocellular carcinoma in the first- and second-line settings.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 24, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Biomarkers in Saliva May Detect Hepatocellular Carcinoma Biomarkers in Saliva May Detect Hepatocellular Carcinoma
MicroRNA biomarkers may provide a means of accurately and remotely testing for this increasingly common cancer, according to a small pilot study ' s results.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 10, 2022 Category: Cancer & Oncology Tags: Gastroenterology News Source Type: news
Sirtex Medical and Grand Pharmaceutical Group Limited receive NDA approval of SIR-Spheres(R) Y-90 resin microspheres in China from the National Medical Products Administration
SIR-Spheres® Y-90 resin microspheres are the first therapeutic radiopharmaceutical approved by the NMPA in 2022
WOBURN, Mass., Feb. 9, 2022 -- (Healthcare Sales & Marketing Network) -- Sirtex Medical ("Sirtex"), a leading manufacturer of ... Devices, Oncology, Regulatory Sirtex Medical, SIR-Spheres, Y-90 resin microspheres, hepatocellular carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 9, 2022 Category: Pharmaceuticals Source Type: news
Researchers restore function in a gene that can suppress liver cancer and enhance immunotherapy
A team builds on COVID-19 mRNA vaccine technology to target specific pathways driving hepatocellular carcinoma. (Source: BWH News)
Source: BWH News - February 9, 2022 Category: Hospital Management Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021
Basel, 3 February 2022Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for newly launched medicines more than offsets impact of biosimilarsDiagnostics Divisionsales grow 29%; strong momentum in base business and continued high demand for COVID-19 testsMajor approvals for medicinessince the last quarter: United States: Susvimo and Vabysmo (age-related blindness)Europe: Gavreto (specific type of advanced lung cancer); Actemra/RoActemra (severe COVID-19); Ronapreve (non-hospitalised COVID-19 patients and prophylaxis)Major appro...
Source: Roche Investor Update - February 3, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021
Basel, 3 February 2022Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for newly launched medicines more than offsets impact of biosimilarsDiagnostics Divisionsales grow 29%; strong momentum in base business and continued high demand for COVID-19 testsMajor approvals for medicinessince the last quarter:United States: Susvimo and Vabysmo (age-related blindness)Europe: Gavreto (specific type of advanced lung cancer); Actemra/RoActemra (severe COVID-19); Ronapreve (non-hospitalised COVID-19 patients and prophylaxis)Major approvals f...
Source: Roche Media News - February 3, 2022 Category: Pharmaceuticals Source Type: news
Risk of HCC in Chronic Viral Hepatitis With Fatty Liver Risk of HCC in Chronic Viral Hepatitis With Fatty Liver
How does fatty liver impact the risk of hepatocellular carcinoma and mortality in patients with chronic viral hepatitis?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 1, 2022 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Neoadjuvant Cemiplimab Promising for Resectable Liver Cancer Neoadjuvant Cemiplimab Promising for Resectable Liver Cancer
Neoadjuvant cemiplimab induced pathological responses in one third of patients with resectable hepatocellular carcinoma in an ongoing phase 2 trial.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - January 28, 2022 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news
Jens Lindberg takes office as CEO of Medivir on January 24
STOCKHOLM, Jan. 17, 2022 -- (Healthcare Sales & Marketing Network) -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that Jens Lindberg will assume his position as CEO on January 24, 2022. Magnus Christensen, who has been interim CFO since the Annual... Biopharmaceuticals, Oncology, Personnel Medivir, hepatocellular carcinoma, liver cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 17, 2022 Category: Pharmaceuticals Source Type: news
HCC Risk in Hepatitis C Stage-3 Fibrosis After SVR With DAAs HCC Risk in Hepatitis C Stage-3 Fibrosis After SVR With DAAs
Do patients with chronic hepatitis C and stage 3 fibrosis remain at risk of hepatocellular carcinoma even after sustained virological response with DAAs?Liver International (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - January 17, 2022 Category: Surgery Tags: Gastroenterology Journal Article Source Type: news
Prediction Model for HCC Occurrence in Patients With HCV Prediction Model for HCC Occurrence in Patients With HCV
The authors present a validated prediction model for hepatocellular carcinoma occurrence after DAA-mediated SVR in patients with hepatitis C.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 28, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
HCC Prevention Should Target Patients With Moderate Fibrosis HCC Prevention Should Target Patients With Moderate Fibrosis
Efforts to prevent hepatocellular carcinoma unrelated to hepatitis or cirrhosis should be focused on individuals with an intermediate degree of liver fibrosis, suggests a large-scale data analysis.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 20, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
CRISPR/Cas9 Gene Editing Boosts Effectiveness of Sonodynamic Therapy for Liver Cancer in Mice CRISPR/Cas9 Gene Editing Boosts Effectiveness of Sonodynamic Therapy for Liver Cancer in Mice
A CRISPR/Cas9 gene editing system increased the therapeutic efficiency of sonodynamic therapy in a mouse model of hepatocellular carcinoma, resulting in a novel synergistic therapeutic approach, researchers say.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - December 17, 2021 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news
DAAs for HCV-related HCC Patients With Multiple Recurrences DAAs for HCV-related HCC Patients With Multiple Recurrences
Does treatment with direct-acting antivirals have a beneficial effect on HCV-related hepatocellular carcinoma patients who have had multiple courses of recurrence?Journal of Viral Hepatitis (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - December 13, 2021 Category: Radiology Tags: Gastroenterology Journal Article Source Type: news
